The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The investment will support the company’s plans to expand its network of specialised surgical hospitals across India.
The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe
Muted movement reflects consolidation phase as investors await earnings triggers
The investment case for health technology in India is frequently overstated in one direction and understated in another
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
Subscribe To Our Newsletter & Stay Updated
